Sorafenib Reduced Significantly Heptopulmonary Shunt in a Large Hepatocelullar Carcinoma

D'Abadie, Philippe;Borbath, Ivan;Goffette, Pierre;Amini, Nadia;Lhommel, Renaud;et.al.
(2019) Clinical Nuclear Medicine — Vol. 44, n° 1, p. 70-71 (2019)

Files

2019_D_Abadie_Clin_Nucl_Med.pdf
  • Open Access
  • Adobe PDF
  • 114.33 KB
Download

Details

Authors
  • D'Abadie, PhilippeUCLouvain
    Author
  • Borbath, IvanUCLouvain
    Author
  • Goffette, PierreUCLouvain
    Author
  • Amini, NadiaUCLouvain
    Author
  • Lhommel, RenaudUCLouvain
    Author
  • et. al.
Abstract
An 81-year-old man with a large hepatocellular carcinoma was referred in our institution for 90Y radioembolization (RE). The preliminary arteriography using 99mTc-macroaggregate albumin demonstrated an important hepatopulmonary shunt. It was an exclusion criterion for RE due to high risks of lung radiations. Then, the patient was treated with sorafenib during 4 months, stopped because of grade 3 toxicity. A second liver arteriography was performed, and 99mTc-macroaggregate albumin imaging showed an important reduction of the lung shunt. Transient therapy with sorafenib permitted to close the lung shunt and was a bridge for RE.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

D’Abadie, P., Borbath, I., Goffette, P., Amini, N., Lhommel, R., & et al. (2019). Sorafenib Reduced Significantly Heptopulmonary Shunt in a Large Hepatocelullar Carcinoma. Clinical Nuclear Medicine, 44(1), 70-71. https://doi.org/10.1097/RLU.0000000000002369 (Original work published 2019)